Sable Bio Announces €3.2M Seed Round to Advance AI Platform for Drug Safety Assessment
By James Dargan · · 1 min read
London-based biotech startup Sable Bio has raised €3.2 million in seed funding to expand its artificial intelligence platform focused on drug target safety analysis. The round was led by MMC Ventures, with participation from Episode 1 Ventures and Seedcamp. Founded in 2023 by former BenevolentAI scientists Dr. Josh Almond-Thynne and Dr. Alex de Giorgio, the company develops AI models designed to predict safety risks in drug discovery and reduce clinical trial failure caused by toxicity.
The platform integrates large-scale biomedical data, scientific literature, and causal inference models to generate safety insights for pharmaceutical researchers. According to Nitish Malhotra of MMC Ventures, the company is addressing a major bottleneck in pharmaceutical research workflows. Sable Bio reports commercial agreements with multiple pharmaceutical companies and plans to use the funding to expand its team, accelerate development, and integrate real-world evidence into its AI systems.
Featured image: Credit: Sable Bio
